Skip to content

Evofem Biosciences, Inc.

EVFM· OTCCore metricsCIK 1618835

Pharmaceutical preparations551 peers

Close
Nov 18, 2025
Market cap
$1.27M
126.69M shares
Filings
804
$4.63M
Q3 2026+4.2% FY25 yoy
$1.00M
Q3 2026N/M FY25 yoy
$740.00K
Q3 2026N/M FY25 yoy
-$841.00K
Q2 2026derivedN/M FY25 yoy
$0.00
Q3 2026N/M FY25 yoy
$317.00K
Q3 2026−22.0% FY25 yoy
$1.27M
—
0.1×
—
—
—

Twelve months to Sep 30, 2026 · derived

Price

$0.010.00%$0.00past year
Nov 18, 2025 · Official close
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$20.18MFY 2025
$20.18M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$20,183,000reported
FY 20242024-12-31$19,363,000reported
FY 20232023-12-31$18,218,000reported
FY 20222022-12-31$16,837,000reported
FY 20212021-12-31$8,244,000reported
FY 20202020-12-31$446,000reported
FY 20192019-12-31$0reported

Capital returns

Dividends and buybacks · FY2017 to FY2022
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2022—$18.00K$18.00K—215.96M sh+28.7%—
FY2021—$0.00$0.00—167.78M sh+101.9%—
FY2018$200.00K—$200.00K—28.16M sh+58.5%—
FY2017$200.00K—$200.00K—17.76M sh+28.4%—

Pharmaceutical preparations

Evofem Biosciences, Inc. is the 154th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Evofem Biosciences, Inc. · CIK 1618835 · Engraved from SEC EDGAR